May 16, 2025

Delandistrogene Moxeparvovec: Efficacy Evidence Questioned

The AAN Guidelines Subcommittee review finds delandistrogene moxeparvovec for DMD failed to meet primary functional outcomes despite FDA approval.

Conexiant

May 16, 2025

CNGB3 Variant Testing Clarifies Genetic Disease Risk

Researchers found that 16 out of 21 CNGB3 gene variants altered RNA splicing, allowing clearer classification of genetic mutations linked to achromatopsia.

Conexiant

May 08, 2025

Joseph Loo: Let’s Fight Chaos with Collaboration

In turbulent times, ASMS President Joseph Loo calls for US researchers to unite, stand resilient, and focus on the continuing mission

The Analytical Scientist

May 08, 2025

Reframing the MacTel Zone

Macular telangiectasia Type 2: reevaluating an overlooked threat to vision

The Ophthalmologist

May 07, 2025

Survival Trends in Melanoma Brain Metastases: Update of Melanoma Graded Prognostic Assessment

In a study reported in Journal of Clinical Oncology, Sperduto et al analyzed trends in survival associated with newly diagnosed melanoma brain metastases and updated the Melanoma Graded Prognostic Ass...

The ASCO Post

May 01, 2025

Health Care Faces New Immigration Reality

Health care facilities face new challenges as sensitive locations policy protecting them from immigration enforcement was rescinded in January 2025, requiring new protocols for patient protection.

Conexiant

May 01, 2025

Current Pipeline for Noninfectious Uveitis

Dilraj Grewal, MD, an associate professor of ophthalmology at the Duke Eye Center in Durham, North Carolina, and associate director of the Duke Reading Center, reviewed investigational therapies currently in late-stage clinical trials that may soon expand the treatment armamentarium for noninfectious uveitis during the Retina World Congress in Fort Lauderdale, Florida.

Retinal Physician

May 01, 2025

Spotlight on Technology & Technique: LYNX LIO Offers Pattern Delivery and Portability

Discover the revolutionary LYNX, a laser indirect ophthalmoscope providing mobile, precise, and comfortable retinal treatments with integrated headset and wireless tablet interface.

Ophthalmology Management

April 30, 2025

FDA Approves FcRn Blocker for Broad gMG Use

The first FcRn blocker for both adult and pediatric generalized myasthenia gravis has been approved by the FDA, based on data showing sustained symptom improvement and IgG reduction in clinical trials.

Conexiant